Stock 1875 TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials TOT BIOPHARM International Company Limited

Equities

1875

HK0000545266

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
1.68 HKD +6.33% Intraday chart for TOT BIOPHARM International Company Limited +8.39% -14.72%
Mar. 15 TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TOT Biopharm's Loss Narrows in January-September Period MT

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 2,241 2,229 2,141 1,638
Enterprise Value (EV) 1 1,745 2,011 2,194 1,466
P/E ratio -4.41 x -7.34 x -7.64 x -27.1 x
Yield - - - -
Capitalization / Revenue 49.5 x 99.1 x 28 x 3.7 x
EV / Revenue 38.5 x 89.4 x 28.7 x 3.32 x
EV / EBITDA -7.06 x -7.65 x -9.78 x -331 x
EV / FCF -10,686,323 x -11,762,271 x -7,219,017 x -7,547,614 x
FCF Yield -0% -0% -0% -0%
Price to Book 2.61 x 3.83 x 6.39 x 2.29 x
Nbr of stocks (in thousands) 570,000 600,467 615,229 772,788
Reference price 2 3.932 3.712 3.479 2.120
Announcement Date 4/28/20 4/15/21 4/28/22 4/27/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 51.61 39.22 45.31 22.49 76.32 442.2
EBITDA 1 -94.79 -222.9 -247.3 -262.9 -224.2 -4.428
EBIT 1 -106.4 -236.6 -271.5 -291.8 -255.5 -38.93
Operating Margin -206.07% -603.3% -599.23% -1,297.33% -334.7% -8.8%
Earnings before Tax (EBT) 1 -148.7 -268.3 -299.3 -288.5 -261.2 -50.05
Net income 1 -148.7 -268.3 -299.3 -288.5 -261.2 -49.92
Net margin -288.11% -684.01% -660.59% -1,282.73% -342.24% -11.29%
EPS 2 -0.5068 -0.9145 -0.8917 -0.5058 -0.4556 -0.0781
Free Cash Flow - -141.9 -163.3 -170.9 -303.9 -194.3
FCF margin - -361.88% -360.42% -760.03% -398.14% -43.94%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 10/29/19 10/29/19 4/28/20 4/15/21 4/28/22 4/27/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 196 515 - - 53.2 -
Net Cash position 1 - - 496 218 - 172
Leverage (Debt/EBITDA) -2.072 x -2.312 x - - -0.2372 x -
Free Cash Flow - -142 -163 -171 -304 -194
ROE (net income / shareholders' equity) - 501% -88.8% -40.1% -56.9% -9.53%
ROA (Net income/ Total Assets) - -28.4% -20% -22% -23.6% -2.47%
Assets 1 - 944.5 1,495 1,312 1,106 2,023
Book Value Per Share 2 0.2600 -0.6300 1.510 0.9700 0.5400 0.9200
Cash Flow per Share 2 0.0800 0.8800 0.9500 0.3800 0.2500 0.5400
Capex 1 134 76.6 36.3 20.5 112 239
Capex / Sales 260.11% 195.43% 80.09% 91.09% 147.11% 54.05%
Announcement Date 10/29/19 10/29/19 4/28/20 4/15/21 4/28/22 4/27/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.555 CNY
Average target price
3.486 CNY
Spread / Average Target
+124.16%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED Stock TOT BIOPHARM International Company Limited
-14.72% 166M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1875 Stock
  4. Financials TOT BIOPHARM International Company Limited